Christoph Thomssen

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Medicine, Oncology, Pharmacology +16

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text

Medicine, Oncology, Breast Oncology +11

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Medicine, Oncology, Surgery +13

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Fátima Cardoso, Elżbieta Senkus, A. Costa et al. · Annals of Oncology · 2018 · 1.2K citations · Full text

Medicine, Oncology, Breast Oncology +16

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14